Alzheimer’s disease drug development pipeline: 2024

Cited by (334)

Items 201–300 of 334

1. The Evolving Global Epidemiology of Presenile Dementia in People Aged Under 65: A 40-year Cross-Sectional Study
   Dan Zhao, Yingjie Luo, Binfa Ouyang · 2025 · Risk Management and Healthcare Policy
2. Polyphyletic screen defines distinct classes of plant-derived natural products that oppose tauopathy
   Chatrawee Duangjan, Xinmin Chang, Paul M. Seidler · 2025 · Life Science Alliance
3. Impulse Dyscontrol Symptoms Are Related to Amyloid Beta in Patients With Subjective Cognitive Decline and Mild Cognitive Impairment
   Ana Luiza Gonçalves Rochetti, Isadora Cristina Ribeiro, Lucas Luchesi Barnes, Liara Rizzi, Ítalo Karmann Aventurato, Brenda Costa Gonçalves, Marjorie Cristina Rocha da Silva, Márcio Luiz Figueredo Balthazar · 2025 · Psychogeriatrics
4. From consortia discovery to biotech creation: An innovative approach to next‐gen Alzheimer's drugs
   Sarah F. Giardina, Alexander E. Culver, Chandrama Ahmed, Christian Mirescu, Adrian L. Oblak, Jared R. Brosch, Brent Clayton, Jeffrey L. Dage, Bruce T. Lamb, Timothy I. Richardson et al. · 2026 · Alzheimer s & Dementia
5. Towards a speech-based digital biomarker for cognitive impairment: speech as a proxy for cognitive assessment
   Jonathan Heitz, Ines Engler, Nicolas Langer · 2026 · npj Digital Medicine
6. Beyond the streetlight: a TREAT‐AD perspective on where to find new Alzheimer's targets
   Gregory A. Cary, Jesse C. Wiley, Gregory W. Carter, Allan I. Levey · 2026 · Alzheimer s & Dementia
7. A compound enhancing lysosomal function reduces tau pathology, microglial reactivity and rescues working memory in 3xTg AD mice
   Zachary Mayeri, Georgia Woods, Anand Rane, A Kifle, Manish Chamoli, Shikha Shukla, Chaska C. Walton, Julie Kay Andersen · 2026 · GeroScience
8. Resource-stratified machine learning framework for cognitive status classification and mild cognitive impairment to dementia progression prediction
   Jingmei Yang, Huitong Ding, Samad Amini, Boran Hao, Cody Karjadi, Rhoda Au, Ioannis Ch. Paschalidis · 2026 · Alzheimer s Research & Therapy
9. PPARG as a central regulator of ferroptosis in Alzheimer’s disease: integrated transcriptomic, single-cell, and experimental evidence
   Lingjia Tang, Ningning Wu, Hong Yan Xu, Yuxuan Mo · 2026 · Frontiers in Aging Neuroscience
10. A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer's disease
    Ambreen Kanwal, Bilal E. Kerman, Shaowei Wang, Kevin Camey, Boyang Li, Lisi Flores Aguilar, Nada Ali, Laura Beth McIntire, Chang April Shu, Stan G. Louie et al. · 2026 · Alzheimer s & Dementia
11. Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
    Alberto Ouro, Gabriel A. Ben-Dor, Manuel Debasa‐Mouce, Shelly Gulkarov, Joshua De Leon, Mónica Castro‐Mosquera, Tomás Sobrino, Anastasia M. Bougea, Allison Bethanne Reiss · 2026 · Frontiers in Cell and Developmental Biology
12. Frailty status and the risk of dementia, Alzheimer’s disease: a meta-analysis of observational studies
    Yannan Zhao, Menglin Zeng, Sheng Zhang, Dezhong Peng · 2026 · Frontiers in Neurology
13. Emerging Roles of Rivastigmine Derivatives Bearing Antioxidant Motifs as Multi-Target Agents for the Management of Neurodegenerative Diseases
    Inês Dias, Catarina Guerreiro-Oliveira, Inês Melo-Marques, Sandra M. Cardoso, Rita Cardoso Guedes, Ismael Carvalho, Teresa Rocha, Daniel Chavarria, Sı́lvia Chaves, Maria Amélia Santos · 2026 · International Journal of Molecular Sciences
14. CSF Biomarker Profile of Cerebral Amyloid Angiopathy: Diagnostic Performance and Imaging Correlates in a Hospital‐Based Neurology Cohort
    Aida Fernández‐Lebrero, Joan Jiménez-Baladó, Greta García‐Escobar, José Contador, Isabel Estragués-Gázquez, Laia Peraferrer-Montesinos, Antoni Suárez‐Pérez, Rosa María Manero-Borràs, Brigitte Beltrán, Ludovica Gramegna et al. · 2026 · European Journal of Neurology
15. A paradigm of the diagnosis and treatment for the whole process of Alzheimer’s disease
    Jing Shi, Yifeng Du, Huali Wang, Nan Zhang, Wei Chen, Jingnian Ni, Xianghui Lu, Yongan Sun, Gang Wang, Jun Liu et al. · 2026 · Annals of Medicine
16. Advances in the treatment of Alzheimer’s disease
    Rezzan Temelli Goceroglu, Ahmet Hacımüftüoğlu · 2026 · Frontiers in Pharmacology
17. Reprogramming Neuroinflammation: Mitochondrial Targets and Immune Checkpoint Inhibitors in Alzheimer’s Disease
    Nishant Kumar, Prince Ahad Mir, Gyamcho Tshering Bhutia, Preeti Chaudhary, Gurpreet Kaur, Qadir Alam, Sharad Daulatrao Pawar, Sukesh Kumar Gupta · 2026 · Molecular Neurobiology
18. Human Microglial Molecular Alterations in Aging and Alzheimer’s Disease
    Karol Ann T. Baldo, Elisa Gozlan, Emmanuel Onyinyechukwu Chidebe, Ifeoluwa Oluleke Awogbindin, Marina Ocaña Prieto, Leslie Michelle M. Dalmacio, Benneth Ben-Azu, Dan Frenkel, Marie‐Ève Tremblay · 2026 · Cells
19. Early-stage research and new pharmacological targets in Alzhei-mer's dementia
    Mihai Grecu, Aurelia Romila, Simona Moldovanu, Alina Condratovici-Plesa, Lucreția Anghel, Violeta Diana Oprea, Laura Alice Bocancia · 2026 · Balneo and PRM Research Journal
20. Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025
    Can Li, Mengyuan Fu, Karina Berg, Joshua David Wallach, Kexin Ling, Ran Wei, Luwen Shi, Joseph S. Ross, Xiaodong Guan · 2026 · Neurology
21. Integrating synthesis, enzyme inhibition and in silico studies: Carbamoyl luteolin derivatives targeting Alzheimer's disease
    The‐Huan Tran, Thi‐My‐Hanh Nguyen, Thi‐Cam‐Nhung Cao, Thai‐Son Tran, Thanh‐Tan Mai, Thanh‐Dao Tran · 2025 · Journal of the Chinese Chemical Society
22. Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT‐AD)
    Joshua D. Grill, Margaret D. Mastrolorenzo, Heather M. Snyder · 2025 · Alzheimer s & Dementia
23. Neurodegenerative Diseases: Pathogenesis and Preclinical Models for Translational Drug Discovery
    Laura Fusaro, Dinesh S. Bangari, R. Jeroen Pasterkamp, Javier Fernández‐Ruíz, Sameh A. Youssef, Alok K Sharma · 2025 · Toxicologic Pathology
24. Donanemab: The dawn of disease-modifying treatment for Alzheimer’s disease in Australia
    Samantha M. Loi, Matthew JY Kang · 2025 · Australasian Psychiatry
25. Tau Clearance Reverses Neuronal Dysfunction in Both Young and Aged C. elegans
    Trae Carroll, Gail V.W. Johnson, Keith W. Nehrke · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
26. Integrative analysis of pooled CRISPR screens provide functional insights into AD GWAS risk genes
    Rebecca Y. Wang, Glenn G. Wozniak, Xiaoting Wang, Meer Mustafa, Malak El Khatib, Elias Kahn, Peter Heutink, Hua Long, Sara Kenkare-Mitra, Arnon Rosenthal et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
27. Alzheimer’s Polygenic Risk Scores Are Not Interchangeable: Evidence from 1,752 Models
    Elizabeth L. Ward, Peter T. Nelson, Yuriko Katsumata, David W. Fardo, Gregory A. Jicha, Alzheimer's Disease Neuroimaging Initiative, Justin B. Miller · 2026 · medRxiv
28. Medicinal Chemistry Strategies to Combat Neurodegenerative Diseases
    Elisa Uliassi · 2024 · Current Topics in Medicinal Chemistry
29. The next chapter in Alzheimer's disease treatment
    Jenna D. Theroux, Adriane B. Marino, Evan S. Drake · 2024 · The Nurse Practitioner
30. Knowledge and Attitudes toward New Disease-Modifying Treatments for Alzheimer's Disease among Nursing Home Directors
    Shiwei Liang, Brian R. Ott, Jennifer Tjia, Kate L. Lapane, Alison C. Rataj, Matthew James Alcusky · 2024 · Journal of the American Medical Directors Association
31. NO classifier prediction of anti neuroinflammatory agents using text mining of 3D molecular fingerprints
    Si Eun Lee, Sang-Jin Ahn, Surendra Kumar · 2024 · Scientific Reports
32. Evaluating the Accuracy of Online and In-Clinic Subjective Cognitive Decline Assessments in Detecting Cognitive Impairment (Preprint)
    Jae Myeong Kang, Manchumad Manjavong, Adam Diaz, Miriam Thiel Ashford, Anna Aaronson, Joseph Eichenbaum, R. Scott Mackin, Rachana Tank, Melanie Jayne Miller, Bernard Landavazo et al. · 2024
33. Co-occurrence of neuropsychiatric symptoms in ADAMS, ADNI and NACC studies as assessed by Neuropsychiatric Inventory
    Галанкин Тимофей Леонидович, Jina Swartz, Hans J. Moebius, Anton Bespalov, the Alzheimer’s Disease Neuroimaging Initiative · 2025 · medRxiv
34. Transferrin receptor-binding blood-brain barrier shuttle enhances brain delivery and efficacy of a therapeutic anti-Aβ antibody
    Marta Ramos Vega, Henrik H. Hansen, Camilla Stampe Jensen, Evdoxia Alexiou, Martin Rønn Madsen, Franziska Wichern, Jacob Lercke Skytte, Casper Graversen Salinas, Florence Sotty, Allan Jensen et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
35. Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)
    Lisa Waterink, Sven J. van der Lee, Dionne M. Nijland, F I van der Zee, Leonie N.C. Visser, Yolande A.L. Pijnenburg, Sietske A.M. Sikkes, Wiesje M. van der Flier, Marissa Deborah Zwan · 2025 · The Journal of Prevention of Alzheimer s Disease
36. Early Alzheimer’s disease: Clinical overview
    James Selwood, Elizabeth Jane Coulthard · 2025 · Elsevier eBooks
37. The calmodulin hypothesis of neurodegenerative diseases: searching for a common cure
    Danton H. O’Day · 2025 · Neurodegenerative Disease Management
38. A Descriptive Statistical Analysis of Neuropsychiatric Symptom Pair Prevalence
    Галанкин Тимофей Леонидович, Jina Swartz, Hans J. Moebius, Anton Bespalov · 2025 · Journal of Geriatric Psychiatry and Neurology
39. Anti-Amyloid-Antikörper: Ein Meilenstein in der Behandlung der Alzheimer-Krankheit: Pro
    Frank Jessen · 2025 · Psychiatrische Praxis
40. «Failures» and current developments in the search for a cure for Alzheimer disease
    E. V. Ganzgorn, S. S. Peglivanov, A.V. Pogrebnyak, T. S. Stumaitis, N. H.‐A. Kiev · 2025 · Glavvrač (Chief Medical Officer)
41. Differential diagnosis of Alzheimer’s disease and vascular cognitive disorders
    M. A. Cherdak, Elen A. Mkhitaryan, О. Н. Ткачева · 2025 · S S Korsakov Journal of Neurology and Psychiatry
42. A New Dawn
    Victor L. Villemagne · 2025 · Journal of Nuclear Medicine
43. Patient attitude towards lecanemab: results from a survey within the European Alzheimer’s disease consortium (EADC), the German memory clinic network (DNG) and Austrian memory centers
    Jonathan Vöglein, Johannes Levin, Elisabeth Stögmann · 2025 · medRxiv
44. Targeted therapy in older adults with Alzheimer disease: a review
    Polina A. Bulina, Polina A. Popova, Lyubov S. Dyatchina, Maria M. Goliatina, A. Zaitseva, Anastasia A. Abramenko, Kirill P. Raevskii · 2025 · Russian Medicine
45. Evaluating the safety and feasibility of remote ischemic conditioning for slowing cognitive decline in mild Alzheimer’s dementia
    Xin Huang, Qiling Ji, Tanna Tong, Lipeng Cai, Omar Elmadhoun, Yanfang Zeng, Xiaokun Geng, Yuchuan Ding · 2025 · Frontiers in Neurology
46. Portable platform for measuring amyloid beta 42/40 ratio via photooxidation-induced fluorescence amplification
    Sanghag Ko, Hyunjun Bae, Daewon Kim, Yeonju Lee, Isaac Choi, Dain Lee, Dong hwan Choi, Hyung Chul Kim, Seo Young Sohn, Yohan Jeong et al. · 2025 · Lab on a Chip
47. Advancing Amyloid Aggregation Research: A Focus on Innovative Therapies, Molecular Modeling and Nano-Delivery Systems in Alzheimer’s Disease
    Umaira Hasan, Himangini Jain, Ruhi Ali · 2025 · Current Drug Targets
48. Fluid and Imaging Markers of Glial Reactivity
    Marc Suárez‐Calvet · 2025 · Springer eBooks
49. Targeting Microglial Phagocytosis for Alzheimer's Disease Management: Natural, Pharmacological, Nanoparticle, and Gene Therapy Approaches
    Shalini Raghuvanshi, Avijit Mazumder, Saumya Das · 2025 · CNS & Neurological Disorders - Drug Targets
50. Comparing and combining TSPO-PET tracers in tauopathies
    Harry Crook, Nicolai Franzmeier, Nesrine Rahmouni, Johannes S. Gnörich, Tim D. Fryer, Young T. Hong, Sebastian Niclas Roemer, Carla Palleis, Alexandra Strauss, Peter Simon Jones et al. · 2025 · medRxiv
51. Alzheimer's Disease: Advances in Early Diagnosis and Emerging Therapeutics
    Pathuni Hema Geethika, Chintapalli Veeravenkata Sireesha, J Devi · 2025
52. Beyond Antibodies: Reinventing Alzheimer’s Treatment for the Next Decade
    Sabrina Garbo, Alessia Raucci, Clemens Zwergel · 2025 · Drug Discovery Today
53. Alzheimer's Disease: A New Paradigm, New Treatments, New Challenges, New Approaches
    Lütfü Hanoğlu, Deniz Eruçar, Tehran Aliyeva · 2025 · Journal of Health Systems and Policies
54. Differential Diagnosis of Alzheimer’s Disease and Vascular Cognitive Disorders
    M. A. Cherdak, Elen A. Mkhitaryan, O. N. Tkacheva · 2025 · Neuroscience and Behavioral Physiology
55. Alzheimer’s disease and the therapeutic potential of theta burst stimulation: A systematic review of preclinical and clinical studies
    Negin Eissazade, Pouria Akbarikoli, Neguine Rezaii, Mohammadreza Shalbafan, Hesam Mosavari · 2025 · medRxiv
56. Tau Enhances Aggregation of S100A9 Protein and Further Association of Its Fibrils
    Lukas Krasauskas, Dominykas Veiveris, Mantas Žiaunys, Darius Šulskis, Andrius Sakalauskas, Vytautas Smirnovas · 2025 · International Journal of Molecular Sciences
57. Computational Insights into Dopamine-Mediated Conformational Transitions of Aβ Aggregates in Alzheimer’s Disease
    Sunandini Swain, Atanu K. Metya · 2025 · ACS Chemical Neuroscience
58. Generation of a recombinant GST-Tau antigen for indirect ELISA in evaluating Alzheimer’s disease vaccines
    Diana Iris Zamora-Loyarte, Karen León‐Arcia, Gabriela Pérez-Leal · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
59. Opposing views or like-minded? International Working Group and Alzheimer’s Association criteria
    Inge M.W. Verberk, Argonde C. van Harten, Wiesje M. van der Flier · 2025 · Brain
60. CSF Biomarker Profile of Cerebral Amyloid Angiopathy: Diagnostic Performance and Imaging Correlates in a Hospital-Based Neurology Cohort
    Aida Fernández‐Lebrero, Joan Jiménez-Baladó, Greta García‐Escobar, José Contador, Isabel Estragués-Gázquez, Laia Peraferrer-Montesinos, Antoni Suárez‐Pérez, Rosa María Manero-Borràs, Brigitte Beltrán, Laura Ludovica Gramegna et al. · 2025 · Research Square
61. Characterization of National Institute on Aging‐Funded Clinical Trials for Alzheimer's Disease
    Kavya M. Shah, Bhav Jain, Abhinav Komanduri · 2025 · Journal of the American Geriatrics Society
62. Analysis of Single Particles of Amyloid Beta and α‐Synuclein With Seeded Amplification for the Diagnosis of Alzheimer's and Parkinson's Disease
    Alexandra Dybala, Marlene Pils, Oliver Bannach, Gültekin Tamgüney, Detlev Riesner · 2025 · Biotechnology and Applied Biochemistry
63. Predicted molecules followed by experimental validation for protecting human neurons from oxidative stress–induced cytotoxicity
    Xuyu Yang, Joo‐Youn Lee, Farbod A. Moghadam, Joseph P. Steiner, Soo‐Kyung Kim, Neha Ganjur, Adrian J. de Almenara, Brian M. Stoltz, Y. Peng Loh, William A. Goddard · 2025 · Proceedings of the National Academy of Sciences
64. Optimierung der Arbeit von Gedächtnisambulanzen unter Gesichtspunkten von „value-based healthcare“ – ein Ansatz aus dem Zentrum für Gedächtnisstörungen der Uniklinik Köln
    Anna R. Schönberger, Ann‐Katrin Schild, Annika Steinmetz, Franziska Simandi, Gloria S. Benson, Lucrezia Hausner, Michael Schöttler, Bastian Hennig, Arne Knudsen, Franziska Maier et al. · 2025 · Der Nervenarzt
65. Alzheimer’s Disease: Pathophysiological and Therapeutical Insights
    Komal Tyagi, Prerna Sarup, Jai Malik · 2025 · Nutritional neurosciences
66. Immune Profiling in Early Cognitive Disorders (IMPRINT) study protocol: a longitudinal cohort study exploring biomarkers of inflammation in early dementia with Lewy bodies and Alzheimer’s disease, as part of the Dementias Platform UK
    Harry Crook, Peter Swann, Haddy K. S. Fye, Stacey L. Kigar, George Savulich, Anna McKeever, Elena Vila Herrero, Lordina Turner, Lina Aimola, Gabrielle Grey et al. · 2025 · BMJ Open
67. Development of Novel 3-Phenylpropanamide Derivatives as BChE Inhibitors for the Treatment of Alzheimer’s Disease
    Haibo Wu, Na Huang, Keren Wang · 2025 · ACS Omega
68. Noninvasive imaging of amyloid‐beta and tau in rodent and nonhuman primate models
    Ruiqing Ni, Axel Rominger · 2025 · Open Research (University of Surrey)
69. Biosimilars: Antibody and nanobody-based therapeutic approaches towards protein misfolding diseases
    Subashchandrabose Chinnathambi, Nagaraj Rangappa · 2025 · Advances in protein chemistry and structural biology
70. Longitudinal analysis of electronic health records reveals medical conditions associated with subsequent Alzheimer’s disease development
    Xue Zhong, Gengjie Jia, Zhijun Yin, Rui Chen, Kerou Cheng, Andrey Rzhetsky, Bingshan Li, Nancy Jean Cox · 2025 · Alzheimer s Research & Therapy
71. Recent Advances and Strategies in Drug Repurposing for Alzheimer’s Disease Therapy
    Sohee Kim, Hanwoong Woo, Sehyun Chae, Jieun E. Kim · 2025 · KSBB Journal
72. The Dementia Cascade: From the Preclinical Stage
    Qin Chen, Jun Xu, Hui Gao, Hanlin Cai · 2026 · Springer eBooks
73. Pharmacological Precision Medicine to Treat Dementia
    Kang‐Po Lee, Po‐Yu Lin, Meng-Ju Wu, Pi‐Shan Sung · 2026 · Springer eBooks
74. An Explainable Clinical NLP Chatbot for Alzheimer's Disease Screening and Treatment Guidance
    Sahana L, Sahana B Raj, Alfiya Rehman · 2025 · International Conference on Applied Artificial Intelligence and Computing (ICAAIC)
75. Cell type–specific gene regulatory atlas prioritizes drug targets and repurposable medicines in Alzheimer's disease
    Yunxiao Ren, Ming Hu, Li Yang, Andrew A. Pieper, Jeffrey L. Cummings, Feixiong Cheng · 2026 · Genome Research
76. Distinct CSF lipidomic profiles are associated with five proteomic subtypes in patients with Alzheimer’s disease
    Georgia Malliou, Lianne Maria Reus, Yolande A.L. Pijnenburg, Wiesje M. van der Flier, Nienke M. de Wit, Serhii Chornyi, Gijs Kooij, Helga E. de Vries, Charlotte Elisabeth Teunissen, Pieter Jelle Visser et al. · 2026 · Molecular Neurodegeneration Advances
77. Multimodal Deep Learning Framework for Alzheimer’s Disease Diagnosis using structural MRI and Genetic features
    Rohit Kumar, Ankush Jain, Surendra Nagar · 2025 · International Conference on Image Information Processing (ICIIP)
78. INNOVATIVE TECHNOLOGIES IN ALZHEIMER’S DISEASE MANAGEMENT: A COMPREHENSIVE REVIEW OF DIAGNOSTIC AI, VIRTUAL REALITY INTERVENTIONS, AND WEARABLE MONITORING SYSTEMS
    Radosław Swędrak, Marzena Swojnóg, Zuzanna Dobrakowska, Jakub Klepacz · 2026 · International Journal of Innovative Technologies in Social Science
79. Effect of magnetic resonance image-based motion correction on the centiloid scale: a comparison with and without correction
    Ryo Yamakuni, Naoyuki Ukon, Takashi Kanezawa, Hironobu Ishikawa, Takeyasu Kakamu, Takenobu Murakami, Keijiro Saito, Motoharu Hakozaki, Hirofumi Sekino, Shiro Ishii et al. · 2026 · Annals of Nuclear Medicine
80. APOE Gene Editing as a Therapeutic Target Toward Precision Medicine in AD
    Bruce Teter, Jesus J. Campagna, Patricia R. Spilman, Varghese John · 2025 · Springer eBooks
81. Design, synthesis and biological evaluation of novel 3,4-dihydro-2(1 H )-quinoline- O -carbamate derivatives as AChE/MAO-B dual inhibitors for the treatment of Alzheimer's disease
    Wanting Fu, Keren Wang, Hongsong Chen, Tao Liu, Xiaojuan Liu, Qishun Jin, Zhenghuai Tan, Wu Dong, Wenmin Liu, Zhi-Pei Sang · 2026 · RSC Medicinal Chemistry
82. Maladaptive aging trajectory in late-onset Alzheimer's disease
    Tao Lv, Huifang Sun, Tengyuan Xia, Man Lu Zhu, Yuhong Li · 2026 · The Innovation Life
83. Beta-Amyloid Suppresses Mitochondrial ATP Production in Human Neuroblastoma Cells
    Yuliya A. Zagryadskaya, Semen V. Nesterov, Vladimir A. Mitkevich, Sergey A. Kozin, Anastasia Kryuchkova, G. Yu. Lomakina, Mikhail S. Karbyshev, Eduard Valeryevich Bocharov, Alexander А. Makarov, Ivan S. Okhrimenko · 2026 · Biochemistry (Moscow)
84. From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials
    Mansi Verma, Niraj Kumar Singh · 2026 · Metabolic Brain Disease
85. Plasma Autoantibodies Against Neurodegeneration-Related Antigens in Dementia and Elevated Chi3Li Autoantibodies in Mild Cognitive Impairment
    Gabriela Kocurova, Zuzana Svabenska, Jan Klaschka, Aleš Bartoš, Jan Říčný · 2026 · Biomolecules
86. Im Windschatten von Amyloid: die Tau-und-Tangle-Hypothese
    Christian Behl · 2026 · Springer eBooks
87. STRONGER 60+: study protocol for a mixed-methods randomised controlled trial assessing the clinical effectiveness and delivery of an adapted FINGER model for brain health in primary care
    Anna‐Karin Welmer, Breiffni Leavy, Charlotta Thunborg, Jasper Holleman, Patrik Karlsson, Helena Hallinder, Malin Aspö, Caroline Dahlgren Bergström, Elisabet Åkesson, Jenni Kulmala et al. · 2026 · BMJ Open
88. Parthenolide Ameliorates Alzheimer’s Disease Pathology by Suppressing Microglial Inflammation and Inflammation-Driven Amyloidogenesis via the HIF1α/NF-κB Axis
    Xin Liu, Jie Liu, Pei-yang Wang, Jun-He Cui, Yu-meng Bu, Shan-shan Wu, Yanhui Zhang, Chuang Guo · 2026 · ACS Chemical Neuroscience
89. Integrative Multi-Omics and Machine Learning Analysis Identifies Therapeutic Targets and Drug Repurposing Candidates for Alzheimer’s Disease
    Bowen Xiao, Yong Q. Chen, Shaopeng Wang · 2026 · Biomedicines
90. Targeting endoplasmic reticulum stress for neuroprotection in ischemia-reperfusion injury: mechanisms and therapeutic approaches
    Nazrana Payal, Rishabh Charan Choudhary, Aditi Sharma, Lalit Sharma · 2026 · Molecular Biology Reports
91. Protein Modifications and Quality Control System: Target for Alzheimer’s Disease Therapy
    Abdullah Md. Sheikh, Shozo Yano, Shatera Tabassum, Jubo Bhuiya, Atsushi Nagai · 2026 · International Journal of Molecular Sciences
92. APOE Gene Editing as a Therapeutic Target Toward Precision Medicine in AD
    Bruce Teter, Jesus J. Campagna, Patricia Spilman, Varghese John · 2026 · Springer eBooks
93. Antibody-Based Medicines Versus Conventional Treatments for Alzheimer’s Disease
    Maria João Ramalho, Stéphanie Andrade, Joana A. Loureiro, Maria C. Pereira · 2026 · Springer handbooks
94. AI-Enabled Early Detection of Alzheimer's Disease Using Medical Imaging
    Mohammad Amreen, Beebi Naseeba · 2026 · International Conference on Computing for Sustainable Global Development
95. Dementia diagnostic deserts: workforce and geographic inequities in the diagnostic pathway for cognitive impairment
    Zhijing Xu, Ying Xue, Yaguang Zheng · 2026 · Health Affairs Scholar
96. Primary prevention of Alzheimer disease in dominantly inherited Alzheimer network: a platform trial design
    Eric McDade, A. Porsteinsson, David B. Clifford, Jorge J. Llibre‐Guerra, G. Wang, Y. Li, S. Belyew, S. Mills, A. Santacruz, Charlene Supnet‐Bell et al. · 2026 · npj Dementia
97. Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025
    Pavlina S. Konstantinova, Jenny Townhill, Juliana Bronzova, Viktoria Andreeva, Swati S. Sathe, Cristina Sampaio · 2026 · Movement Disorders
98. Efficacy of a language‐concordant community health worker intervention to improve community‐to‐clinic linkage for dementia care: results of the randomized trial PLAN
    Hae‐Ra Han, Nancy Perrin, Ji-Young Yun, Deborah Min, Simona C. Kwon, Jinhui Joo, Ji-Young Cho, Sara Kim, Hochang Benjamin Lee · 2026 · Alzheimer s & Dementia
99. Advances in anti-tau therapeutics for alzheimer’s disease: immunotherapy, gene modulation, and combination approaches
    Himanshu Mishra, Manoj Kumar Mishra · 2026 · Molecular Biology Reports
100. IL-4 in Alzheimer’s Disease—Mechanisms and Therapeutic Potential
     Guangya Liu, Wenhua Li, Jiangmin Chen, Shuyu Xu, Xinyuan Liu, Zijie Wang, Qihui Yang, Anqi Xie, 杜艳军 · 2026 · Molecular Neurobiology